### Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 4

#### LA JOLLA PHARMACEUTICAL CO

Form 4

Stock

September 22, 2014

<b>FORM</b>	1 <u>1</u>								_	PPROVAL		
	UNITED	STATES		ITIES All hington,			NGE (	COMMISSION	OMB Number:	3235-0287		
Check this box if no longer subject to Section 16. Form 4 or Form 5  Filed pursuant to Sec				SECURI	ITIES				Expires: Estimated a burden hou response	rs per		
obligatio may con <i>See</i> Instr 1(b).	ons tinue. Section 17(	a) of the	Public Ut		ing Com	pany	Act of	f 1935 or Section	on			
(Print or Type	Responses)											
TIDMARSH GEORGE F Symb			Symbol LA JOL	Issuer Name <b>and</b> Ticker or Trading nbol JOLLA PHARMACEUTICAL				5. Relationship of Reporting Person(s) to Issuer  (Check all applicable)				
(Last) (First) (Middle) 3. Date of (Month/D) C/O LA JOLLA PHARMACEUTICAL			f Earliest Transaction Day/Year)				_X_ Director 10% Owner X Officer (give title Other (specify below) below)  President, CEO & Secretary					
	Y,, 4660 LA JOLI DRIVE, SUITE 1											
(Street) 4. If Amendment, D Filed(Month/Day/Yea					Day/Year) A			Applicable Line)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
SAN DIEG	O, CA 92122								More than One Re			
(City)	(State)	(Zip)	Table	e I - Non-Do	erivative S	Securi	ities Acc	quired, Disposed o	f, or Beneficial	ly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution any	med on Date, if Day/Year)	3. Transactio Code (Instr. 8)		4 and (A) or	d of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			
Common Stock	09/18/2014			Code V P	Amount 5,000	(D)	Price \$ 9.18	1,415,086	D			
Common								20,000	I	By		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control

children

### Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 4

#### number.

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5.	6. Date Exerc	cisable and	7. Titl	e and	8. Price of	9. Nu
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orNumber	Expiration D	ate	Amou	nt of	Derivative	Deriv
Security	or Exercise		any	Code	of	(Month/Day/	Year)	Under	lying	Security	Secui
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivative	e		Securi	ities	(Instr. 5)	Bene
	Derivative				Securities			(Instr.	3 and 4)		Owne
	Security				Acquired						Follo
					(A) or						Repo
					Disposed						Trans
					of (D)						(Instr
					(Instr. 3,						
					4, and 5)						
									Amount		
						Date	Expiration		or Number		
						Exercisable	Date		of		
				Code V	(A) (D)				Shares		
				Code V	(A) $(D)$				Shares		

## **Reporting Owners**

Reporting Owner Name / Address	Relationships						
F	Director 10% Owner Officer		Officer	Other			
TIDMARSH GEORGE F C/O LA JOLLA PHARMACEUTICAL COMPANY, 4660 LA JOLLA VILLAGE DRIVE, SUITE 1070	X		President, CEO & Secretary				
SAN DIEGO, CA 92122							

## **Signatures**

/s/ George F. 09/22/2014 Tidmarsh

\*\*Signature of Date
Reporting Person

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2